SAVI Dual[™] Migraine Therapy from eNeura

— for acute and preventive treatment

- FDA cleared, prescription non-drug therapy for patients 12 and older
- Similar efficacy to prescription medication
- Only non-invasive, Central Neuromodulation therapy for migraine
- No medication risks or side effects
- SAVI Smart Diary[™] automatically records treatment history

www.eneura.com

- Easy patient-administered
- Effective non-drug option
- Superior tolerability
- Quick less than a minute
- Personalized treat as needed
- SAVI Smart Diary ™ automatically records treatment history

SAVI Dual[™] Migraine Therapy

Migraine relief is as easy as 1-2-3



Power

Press center button to turn on device

- Position
 Cradle SAVI Dual to the back of the head
- Press treatment button to deliver a pulse

Repeat as Prescribed

Watch the SAVI Dual "How to" video at www.eneura.com



How SAVI Dual[™] works

Quieting The Migraine Storm

Non-invasive, *Central Neuromodulation* therapy developed to **treat acute attacks** and **prevent future migraine days**



Source: Andreou AP, Holland PR, Akerman S, et al. Transcranial magnetic stimulation and potential cortical and trigeminothalamic mechanisms in migraine. Brain 2016; 139: 2002–2014.

- Electromagnetic fields pass painlessly through bone and tissue
- Non-Invasive pulses signal the brain to calm hyperactive nerves and return to a more natural state
- Safety well established –science used in MRI's for decades
- Single pulse delivered in less than a second
- Often referred to as Single Pulse Transcranial Magnetic Stimulation (STMS)
- Pulse strength about half that of typical MRI



Watch the SAVI Dual "Quieting the Migraine Storm" video at www.eneura.com



Well-established efficacy and tolerability

Proven effective


- Pain freedom 2 hours post treatment
- Sustained pain freedom at 24 and 48 hours

Demonstrated tolerability

• AEs were minimal and mild– 5% SAVI vs 2% sham

SAVI Dual[™] for acute treatment of migraine

Significant and sustained pain freedom





More patients with fewer headache days


-2.75 ± 0.4 less headache days with SAVI treatment vs placebo

Significantly reduced use of acute rescue medications by 3.18 days


Source: Starling AJ et al. *Cephalalgia*. 2018. ESPOUSE Study

SAVI Dual[™] for preventive treatment of migraine

50% responder rate



Mean reduction in headache days





SAVI Dual™ Migraine Therapy

Well-tolerated with no serious adverse events

SAVI Dual is contraindicated for patients with conductive metal implants in the head and neck, excluding dental work.

MRI protocols may be a reasonable guide in assessing use of SAVI Dual in patients with metal implants in the head and neck.

Refer to the Prescriber IFU for a complete list of contraindications and warnings.

5 most common adverse events were mild and typically resolved immediately after treatment



Momentary light headedness





Tingling sensation at time of treatment



Brief ringing in ears (tinnitus)



Dizzy sensation during treatment



Unresolved headache

2% (n=5)

N=217

Source: Starling AJ et al. Cephalalgia. 2018 [epub ahead of print].



Clinical Studies and RWE from tertiary headache clinics

- High frequency, refractory patients
- Failed numerous acute and preventive medications
- Well-tolerated with no serious adverse events

Sources:


- Bhola R, et al. Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: Evaluation of outcome data for the UK post market pilot program; . J Headache Pain 2015 16: 535
- Bhola R, et al. Use of Single Pulse Transcranial Magnetic Stimulation (sTMS) to Treat Migraine with Medication Overuse: Response Over Time. Presented at: 2019 American Headache Society Annual Meeting; July 11-14, 2019; Philadelphia, PA. P2221 B
- Lloyd JO, et al Single-Pulse Transcranial Magnetic
 Stimulation for the preventive treatment of difficult-to-treat
 migraine: a 12-month prospective analysis. J Headache Pain 2023

SAVI Dual™ Real-World Evidence –

Mirrors Clinical Trial Results



Reduction in Headache Days



Reduction in Medication Overuse Headache



• Sustained Response at 3, 6 and 12 months



American Headache Society
(AHS) Prescribing Guidelines Dual
Migraine Therapy with
Neuromodulation

Diagnosis of ICHD-3 migraine with aura, migraine without aura, or chronic migraine

- Inability to tolerate migraine specific medications
- Limits to medication due to comorbid and coexisting illness or concomitant medication
- Adjunctive treatment in those experiencing frequent attacks who are at risk of developing medicationoveruse headache and/or chronic migraine
- Patients who prefer to avoid systemic medications

Source:

Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021 Jun 23 Marcus SC, Shewale AR, Silberstein SD, et al. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response. Cephalalgia. 2020;40(7):639-649

Prescribing SAVI Dual[™] Migraine Therapy

— For patient selection, AHS guidelines are a good place to start

Over 80% of Patients
Discontinue
Preventive
Medications

Additional considerations in patient selection:

- Frequent migraine- need both acute and preventive therapy
- Women of childbearing age concerned about medication use
- History of treatment compliance
 - Patients who use SAVI Dual as prescribed are far more likely to see significant improvement in overall well being
- Reasonable expectations for preventive therapy It may take a few months for preventive therapy to kick in



Comparing Neuromodulation Devices

	FDA Cleared for Acute + Preventive Treatment of Migraine			
	SAVI Dual™	CEFALY®	gammaCore™	Nerivio [®]
Mechanism	Central Neuromodulation	Peripheral Neuromodulation Transcutaneous Electrical Nerve Stimulation (TENS)*		
Met Primary Endpoint ^{1,2}				
Acute (Therapeutic Gain)	Yes (17%) ³	Yes** (7%) ⁴	No (-) ⁵	Yes (19%) ⁶
Preventive (Therapeutic Gain)	Yes (26%) ⁷	No (-) ⁸	No (-) ⁹	Yes (15.9%) ¹⁰
Availability	Rx	ОТС	Rx	RX
Treatment Duration	10 sec	120 mins	4 mins	45 mins
Remote Therapeutic Monitoring (RTM) Automated compliance /Outcome	Yes	No	No	No
Pricing includes unlimited treatment	Yes	No	No	No

Therapeutic Gain = Active response – Placebo response (sources available upon request) Pricing sources: Federal Supply Schedule (2023), company websites

^{**}Pain Status measured immediately after 2 hours of continuous treatment.



¹Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia.

²Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia.

³ Lipton RB, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: A randomized, double-blind, parallel-group, sham-controlled trial. Lancet Neurol 2010; 9: 373–380 4 Kuruvilla, D.E., Mann, J.I., Tepper, S.J. et al. Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM). Sci Rep 12, 5110 (2022).

^{*}Grassorelli C, Grazzi L, de Tommaso et al. Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study. Neurology. 2013 Jul 24,914.2034–2373.

evamitisky D. Dodick DW, Grosberg BM, et al, Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Headache.

*Polener HC, Goadsby PJ, Ashina M, et al. Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine:

^{*}Diener HG, Goadsby PJ, Ashina M, et al. Non-invasive vagus nerve sumulation (nVNS) for the preventive treatment of episodic migral The multicentre, double-blind, randomised, sham-controlled PREMIUM trial. Cephalalgia. 2019 Oct;39(12):1475-1487.

¹⁰ Tepper SJ, Rabany L, Cowan RP et al. Remote electrical neuromodulation for migraine prevention: A double-blind, randomized, placebo-controlled clinical trial. Headache. 2023; 63:377–389.

^{*}TENS devices available over the counter for the treatment of pain in various product configurations, and price ranges

Well-tolerated: treat as needed to improve overall wellbeing

Prescription includes plenty of pulses for daily preventive treatment and for treating migraine attacks as prescribed

Sample Treatment Plan based on SAVI Dual clinical studies:

Daily preventive treatment:

4 pulses twice daily

Acute Treatment:

- 4 pulses at the first sign of the migraine attack
 the earlier, the better
- If needed, treat again every 15-30 minutes until migraine attack subsides

SAVI Dual[™] Migraine Therapy Suggested Treatment Plan

Unlimited, Personalized treatment puts the patient in control



- Takes less than a minute
- Treat as early and often as needed
- Encourage patient to use SAVI Dual for 3 months before adjusting therapy


To learn more, review the SAVI Dual Patient Quick Guide at www.eneura.com/support



Allows patient to quickly record key data in about 15 seconds

- Patient can work with HCP to personalize treatment programs and optimize overall well-being
- Compliant with PHI Standard
- Patients can login directly from eNeura website

SAVI Smart Diary[™] for your patients Secure, wireless headache diary made easy



Clinicians and patients can easily track treatment progress




tracks and records

treatment history

Remote Therapeutic Monitoring (RTM)

- Allows you and your patients to monitor migraine patterns and treatment progress
- Work with your patients to personalize treatment programs and optimize overall well-being
- Treatment Journey compares patient's baseline data to SAVI Dual treatment data

SAVI Dual™ Remote Therapeutic Monitoring (RTM) for Healthcare Providers



To access SAVI RTM, login at eNeura.com - click HCP login

To learn more about SAVI RTM, review the SAVI Remote Therapeutic Monitoring (RTM) Quick Guide at https://www.eneura.com/for-healthcare-professionals/



eNeura provides your patient one-to-one support

Personalized Patient Support

eNeura's **Customer Care team** is here to answer any questions your patient may have, such as how to fill or renew their prescription or take care of their SAVI Dual.

The dedicated eNeura Clinical Specialist will walk your patient through their first treatment, step-by-step. They will find it remarkably easy.





Company Information

eNeura Inc. is a wholly-owned subsidiary of Aruene Corporation

Aruene Corporation 101 W. Dickman St, Ste 900 Baltimore, MD 21230

UEI: KPYXBLSSLCM5


Cage Code: 8YSK9


Email: customercare@eneura.com

Fax: 877.264.1818

Phone: 833.499.9300, option 1

How to prescribe SAVI Dual[™] Migraine Therapy







Ordering Information

Item # 16140-0020-13-3 3-month activation of SAVI Dual Migraine Therapy

Item # 16140-0020-13-12 12-month activation of SAVI Dual Migraine Therapy

Activation purchase includes:

- Unlimited use of SAVI Dual for acute and preventive migraine therapy during the activation period
- Patient access to wireless SAVI Smart Diary
- HCP access to SAVI Remote Therapeutic Monitoring (RTM)



SAVI Dual[™] Migraine Therapy from eNeura

- for acute and preventive treatment
- FDA cleared, prescription non-drug therapy for patients 12 and older
- Similar efficacy to prescription medication
- Only non-invasive, Central Neuromodulation therapy for migraine
- No medication risks or side effects
- SAVI Smart Diary[™] automatically records treatment history

www.eneura.com

SAVI Dual[™] Migraine Therapy

Available Resources at www.eneura.com:

Click the HCP tab for:

- ✓ SAVI Dual Quick Guide also ships with every device
- ✓ SAVI Remote Therapeutic Monitoring (RTM) Quick Guide
- √ How to prescribe

Click the Clinical Data and Publications tab for:

- ✓ Clinical trials and studies
- ✓ Real world evidence
- √ Safety data
- ✓ Mechanism of Action
- ✓ Professional Guidelines



